See more : MobileSmith, Inc. (MOSTQ) Income Statement Analysis – Financial Results
Complete financial analysis of Taysha Gene Therapies, Inc. (TSHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Taysha Gene Therapies, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tenaris S.A. (TEN.MI) Income Statement Analysis – Financial Results
- Enbee Trade and Finance Limited (ENBETRD.BO) Income Statement Analysis – Financial Results
- Energy Fuels Inc. (0UU0.L) Income Statement Analysis – Financial Results
- Champion Iron Limited (CIAFF) Income Statement Analysis – Financial Results
- Foshan NationStar Optoelectronics Co.,Ltd (002449.SZ) Income Statement Analysis – Financial Results
Taysha Gene Therapies, Inc. (TSHA)
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 15.45M | 2.50M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 2.49M | 492.00K | 9.00K | 0.00 |
| Gross Profit | 15.45M | 15.00K | -492.00K | -9.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 0.60% | 0.00% | 0.00% | 0.00% |
| Research & Development | 56.78M | 91.17M | 131.94M | 31.89M | 987.00K |
| General & Administrative | 30.05M | 37.36M | 41.32M | 11.11M | 512.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -384.00K |
| SG&A | 30.05M | 37.36M | 41.32M | 11.11M | 128.00K |
| Other Expenses | 1.07M | -18.00K | 0.00 | -17.03M | 0.00 |
| Operating Expenses | 87.89M | 128.53M | 173.27M | 43.00M | 1.12M |
| Cost & Expenses | 87.89M | 128.53M | 173.27M | 43.00M | 1.12M |
| Interest Income | 3.57M | 249.00K | 172.00K | 49.00K | 0.00 |
| Interest Expense | 5.00M | 3.80M | 1.43M | 28.00K | 0.00 |
| Depreciation & Amortization | 1.37M | 2.49M | 492.00K | 9.00K | 4.46M |
| EBITDA | -105.20M | -159.73M | -172.78M | -42.99M | 0.00 |
| EBITDA Ratio | -680.84% | -5,027.82% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.44M | -162.45M | -173.27M | -43.00M | -1.12M |
| Operating Income Ratio | -468.83% | -6,492.69% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -39.13M | -3.57M | -1.26M | -17.01M | 0.00 |
| Income Before Tax | -111.57M | -166.01M | -174.52M | -60.01M | -1.12M |
| Income Before Tax Ratio | -722.06% | -6,635.25% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.57M | 936.00K | -17.01M | -4.46M |
| Net Income | -111.57M | -169.58M | -175.46M | -43.00M | -1.12M |
| Net Income Ratio | -722.06% | -6,777.82% | 0.00% | 0.00% | 0.00% |
| EPS | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| EPS Diluted | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| Weighted Avg Shares Out | 116.12M | 43.95M | 37.65M | 17.67M | 36.99M |
| Weighted Avg Shares Out (Dil) | 116.12M | 43.95M | 37.65M | 17.67M | 36.99M |
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September...
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates
Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.38 per share a year ago.
Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements across consistent clinical domains and an encouraging safety profile in adult (up to 52 weeks) and pediatric (up...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, July 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on July...
Why Is Taysha Gene Therapies (TSHA) Stock Down 14% Today?
Taysha Gene Therapies (NASDAQ: TSHA ) stock is taking a beating on Wednesday after the gene therapy company announced a proposed public offering for its shares. Taysha Gene Therapies says that it intends to offer up to $75 million worth of...
Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.2% on Wednesday.
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has...
What's Going On With Taysha Gene Therapies Stock Tuesday?
Tuesday, Taysha Gene Therapies Inc TSHA released longer-term clinical data from the ongoing REVEAL Phase 1/2 adolescent and adult trial and initial clinical data from the REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in Rett syndrome.
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome
Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with different...
Source: https://incomestatements.info
Category: Stock Reports